IASO Bio and Innovent Enhance Strategic Collaboration in Cell Therapy

Ms. Zhang Jinhua, Founder, Chairwoman and CEO of IASO Bio, stated: “We extend our gratitude to Innovent for their recognition and trust in our research and development capabilities as well as our commercialization strength. Over the past six years, we have built a solid partnership with Innovent and witnessed each other’s innovation and growth in the biopharmaceutical field. We firmly believe that this new strategic alliance will bring significant synergistic effects to both parties. We can fully leverage our strengths and work together to advance innovative therapeutic solutions. We will remain committed to our original mission of bringing more innovative treatments to patients and look forward to achieving mutual success in our future strategic partnership with Innovent.”

Share:

More News

“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy

“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of

“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data